Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31661821 | 1.00 | DGAT1 (0.53) | DGAT1NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL16074592 | 0.85 | DGAT1 (0.50) | DGAT1NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL2132503 | 0.84 | DGAT1 (0.40) | DGAT1NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL194112 | 0.82 | CES2 (0.52) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL3455630 | 0.80 | ESR1 (0.37) | DGAT1ALDH1A1 | |
| SCHEMBL20600120 | 0.80 | LOXL2 (0.40) | LMNASMN1; SMN2KMT2AHPGDKDM1A | |
| SCHEMBL13234347 | 0.79 | DGAT1 (0.45) | DGAT1NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL16029046 | 0.79 | DGAT1 (0.45) | DGAT1NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL4586556 | 0.78 | CYP11B2 (0.43) | NPC1RAB9ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL1439041 | 0.78 | CRBN (0.37) | DGAT1LMNAALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151705-A1 | NOVEL INHIBITORS OF DNA DAMAGE REPAIR PATHWAY | VRISE THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| EP-3845540-A1 | INTERMEDIATES FOR THE SYNTHESIS OF BENZOXAZEPIN COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2021-07-07 | — | — | EP | disclosed |
| EP-3845540-A1 | INTERMEDIATES FOR THE SYNTHESIS OF BENZOXAZEPIN COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2021-07-07 | — | — | EP | disclosed |
| EP-3404032-A2 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2018-11-21 | — | — | EP | disclosed |
| US-9926308-B2 | N-cyclopropyl-N-piperidinyl-amides, pharmaceutical compositions containing them and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-27 | — | — | US | disclosed |
| EP-2880027-B1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2016-09-28 | — | — | EP | disclosed |
| US-20160159784-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-06-09 | — | — | US | disclosed |
| US-9303043-B2 | Process for making benzoxazepin compounds | GREENTECH, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9303043-B2 | Process for making benzoxazepin compounds | GREENTECH, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9303043-B2 | Process for making benzoxazepin compounds | GREENTECH, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| EP-2531198-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | Argusina Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20120004198-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | ARGUSINA INC. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2011097300-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | ARGUSINA, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-11 | — | — | US | disclosed |
| EP-1549640-A4 | 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)AZETIDINE-3-CARBOXYLATES AND 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)PYRROLIDINE-3-CARBOXYLATES AS EDG RECEPTOR AGONISTS | MERCK & CO INC (US) | 2008-08-06 | — | — | EP | disclosed |
| US-7199142-B2 | 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists | MERCK & CO., INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-20050245575-A1 | 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists | MERCK & CO., INC. | 2005-11-03 | — | — | US | disclosed |
| EP-1549640-A2 | 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)AZETIDINE-3-CARBOXYLATES AND 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)PYRROLIDINE-3-CARBOXYLATES AS EDG RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004035538-A1 | PROCESS FOR MAKING AZETIDINE-3-CARBOXYLIC ACID | MERCK & CO., INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003105771-A2 | 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)AZETIDINE-3-CARBOXYLATES AND 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)PYRROLIDINE-3-CARBOXYLATES AS EDG RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | OXA1L, PDK4, MLYCD | DGAT1 4245/4885NPC1 3916/4885RAB9A 4328/4885 |
| US-20120004198-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, GPR119 | DGAT1 2544/4885NPC1 1239/4885RAB9A 2137/4885 |
| US-20050245575-A1 | 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists | EDNRA, OXGR1, EDNRB | DGAT1 3883/4885NPC1 1817/4885RAB9A 1517/4885 |
| US-20160159784-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF | GPR119, FFAR1, FFAR2 | DGAT1 252/4885NPC1 143/4885RAB9A 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.